Companies › Ellipses Pharma
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EP0031 (Lunbotinib) RET inhibitor | RET | Phase 1 | NSCLC | Mar 2027 |
| EP0042 | – | Phase 1 | Acute Myeloid Leukemia | Dec 2027 |
| EP0062 Selective androgen receptor modulator (SARM) | AR | Phase 1 | Hormone Receptor-positive Breast Cancer | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05443126 | EP0031 (Lunbotinib) | Phase 1 | NSCLC | Oncology | Mar 2027 |
| NCT04581512 | EP0042 | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2027 |
| NCT05573126 | EP0062 | Phase 1 | Hormone Receptor-positive Breast Cancer | Oncology | Feb 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.